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Abstract: Hydroquinone (HQ) is an anti-hyperpigmentation agent with poor physicochemical 
stability. HQ formulations are currently elaborated by compounding in local pharmacies. 
Variability in the characteristics of HQ topical formulations can lead to remarkable differences in 
terms of their stability, efficacy, and toxicity. Four different semisolid O/W formulations with 5% 
HQ were prepared using: i) Beeler´s base plus antioxidants (F1), ii) Beeler´s base and dimethyl 
isosorbide (DMI) as solubiliser (F2), iii) olive oil and DMI (F3), and iv) Nourivan®, a skin-
moisturising and antioxidant base, along with DMI (F4). Amongst the four formulations, F3 showed 
the greatest physicochemical stability with less tendency to coalescence but with marked chromatic 
aberrations. An inverse correlation was established by multivariate analysis between the mean 
droplet size in volume and the steady-state flux, which explains why F3, with the smallest droplet 
size and the most hydrophobic excipients, exhibited the highest permeation across both types of 
membranes with enhancement ratios of 2.26 and 5.67-fold across Strat-M® and mouse skin, 
respectively, compared to F1. It is crucial to understand how the HQ is formulated, bearing in mind 
that the use of different excipients can tune the transdermal delivery of HQ significantly. 
Keywords: hydroquinone; transdermal delivery; Franz cells; permeability enhancers; stability; 
multivariate analysis  
 
1. Introduction 
Currently, hydroquinone (HQ) ointments and creams are one of the most frequent types of 
formulations prescribed by dermatologists to treat the hyperpigmentation of the skin [1]. HQ is used 
as an anti-hyperpigmentation agent in skin-lightening formulations at different strengths up to 10% 
(w/w), although the most common concentration ranges between 4–5% (w/w) [2,3]. The poor 
physicochemical stability of HQ topical formulations is a crucial problem that has led to low interest 
within the pharmaceutical industry for the manufacturing of HQ topical formulations; thus, patients 
need to rely on extemporaneously produced products prepared by community pharmacies. The 
chemical instability of HQ can lead to the formation of p-benzoquinone (pBQ), which is carcinogenic, 
and the production of other compounds that lead to dark chromatic aberrations [4–6]. The 
hydrophilic nature of HQ is an extra challenge in developing topical formulations, as its permeability 
is limited unless an appropriate penetration enhancer is included in the extemporaneous prepared 
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topical products [7–9]. However, if HQ is not localised in the skin, it can lead to severe adverse effects 
due to its systemic absorption such as hepatotoxicity, nephrotoxicity, and neurobehavioural 
alterations [10,11]. Thus, variability in the physicochemical characteristics of different HQ 
formulations can lead to remarkable differences in terms of its stability, efficacy, and toxicity, and it 
is an interesting topic of research due to its significant clinical implications.  
The hypothesis underpinning this work is that the transdermal permeation enhancers utilised 
in the manufacturing of topical HQ formulations may have a significant effect on both the stability 
and the permeability (efficacy versus toxicity) across the skin, which should be taken into 
consideration by dermatologists when prescribing. Thus, we aim to compare the physicochemical 
stability and permeability of four different HQ topical formulations with a dose strength of 5% using 
a variety of permeation enhancers commonly employed in the extemporaneous compounding of HQ. 
Four different semisolid oil in water (O/W) formulations (coded as F1–F4, see Table 1) were prepared. 
F1 was manufactured using the conventional Beeler´s base (which is an anionic o/w emulsion 
containing sodium lauryl sulphate as surfactant, Acofarma® 2018 [12]). Beeler’s base has been selected 
as a reference formulation, as currently, the preparation of HQ topical formulations by Spanish 
community pharmacies is based on this base. Antioxidant agents such as vitamin C and E were also 
incorporated to reduce HQ oxidation. F2 to F4 included dimethyl isosorbide (DMI) instead of 
propylene glycol, as it has been reported to be a suitable permeation enhancer for HQ with less 
toxicity [13]. Beeler´s base was also utilised in the preparation of F2, whereas an olive oil base 
supplement consisting mostly of oleic acid was used in the preparation of F3, and Nourivan® base 
was employed in the preparation of F4. Nourivan® base was selected due to its skin-moisturising and 
antioxidant properties, which is of special importance in the extemporaneous dispensing of drugs 
susceptible to oxidation such as HQ (Fagron®, 2018) [14]. The conventional pH for hydroquinone 
topical formulations is preferably acidic, and generally below or close to a pH of 4, even though this 
can be harsh to the skin and possibly other components of the product. Hydroquinone is more stable, 
and less likely to discolour under acidic conditions. Variations in pH have been shown to result in 
marked discoloration [5,15]. 
Table 1. Composition of the four developed hydroquinone (HQ) formulations expressed in weight 
percentage. Key: DMI: Isosorbide dimethyl ether, PG: Propylene glycol, Vit. C: Vitamin C, Vit. E: 
Vitamin E. Further details in Tables S1 and S2. 
Formulation 
HQ 
(%) 
PG 
(%) 
Vit. C 
(%) 
Vit E 
(%) 
DMI 
(%) 
Beeler´s 
base (%) 
Olive oil 
base* (%) 
Nourivan® 
(%) 
pH 
F1 5 5 1.25 1.25 - 87.5 - - 3.6 
F2 5 - - - 15 80 - - 3.7 
F3 5 - - - 15 - 80 - 3.6 
F4 5 - - - 15 - - 80 3.2 
*The base contains 2.5% oleic acid and 1.8% α-tocopherol acetate.  
2. Materials and Methods  
2.1. Materials 
HQ USP quality was donated from Cantabria Laboratories (Madrid, Spain). pBQ (>98%) was 
supplied by Sigma-Aldrich (Madrid, Spain). Beeler’s base was supplied by Acofarma (Madrid, 
Spain), while Nourivan® was supplied by Fagron Ibérica (Madrid, Spain). All of the excipients were 
of pharmacopoeia grade. 
2.2. Preparation of HQ Formulations (F1–F4) 
The composition of the four O/W cream formulations is illustrated in Table 1. Briefly, HQ was 
finely grounded and then either dispersed in propylene glycol (PG) or dissolved in DMI using a 
mortar and pestle. Then, the corresponding base (Beeler´s base, olive oil, or Nourivan®) was 
incorporated and mixed in the mortar and pestle. Dissolved Vitamin C (Vit. C) and E (Vit. E) were 
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added in F1 at the end of the process. An Unguator mixer (Microcaya, Bilbao, Spain) was employed 
between 3–5 min in order to ensure a homogenous semisolid mixture. Once prepared, the final pH 
was measured and reported in Table 1. 
2.3. Physicochemical Characterisation of HQ Formulations 
A particle size analyser (Microtrac S3500, Microtrac, PA, USA) was used for determination of 
the mean particle size and particle size distribution of HQ formulations. The size and distribution of 
the prepared formulations were expressed by the volume median diameter (MV) and the D10, D50, 
and D90 (indicating the percentages of particles having 10%, 50%, and 90% of the diameter equal to 
or lower than the given value). The span was calculated as a measure of polydispersity using the 
following equation: 
Span= (D90–D10)/D50                              Equation (1) 
Prior to measurement, HQ formulation samples were diluted (1/100) with deionised water. Each 
sample was measured in triplicate [3,16]. 
The rheological behavior of the formulations was evaluated in triplicate using a Brookfield 
(Middleborough, MA, USA) Model DV-III fitted with a temperature control probe. A 5-cm cone–plate 
measuring geometry was used. The temperature of all the measurements was maintained at 25 °C. 
Viscosity (cP) and shear stress (D × cm−2) were determined over a speed rate from 0 to 15 rpm, and a 
shear rate from 0 to 30 (1/s). Prior to measurements, a standard of 311.25 Pa·s was analysed [17]. 
Apparent water content (%) was evaluated as weight loss. The loss of mass was measured by an 
infrared balance (Mettler PM100 and LP16, Columbus, OH, USA). The final point was set up to 120 s 
without weight loss and heated at 105 °C. 
2.4. Physicochemical Stability Studies 
The physical stability of HQ formulations including size and size distribution was evaluated at 
different time points after storage at three different temperatures: 6 °C, 25 °C, and 40 °C. Chemical 
stability was also analysed at the same time by high-performance liquid chromatography (HPLC). 
HQ formulations (0.1 g) were dispersed in 10 mL of deionised water followed by 10 min of bath 
sonication and centrifugation (8000 rpm, 10 min). Supernatants were filtered by 0.45 µm using a 
hydrophilic polytetrafluoroethylene (PTFE) filter (Millipore Millex-LCR®, Billerica, MA, USA) and 
subsequently diluted 1 in 100 with mobile phase and analysed by HPLC (see method below 
described) for HQ and p-benzoquinone (pBQ) quantification. The degradation rate of HQ 
formulations was calculated by fitting the percentage of HQ degraded at different time points to a 
first-order reaction. The Arrhenius equation was used in order to estimate the activation energy and 
the effect of temperature on the degradation rates of HQ (Equation (2)). 
  =   
   
                                 Equation (2) 
Where K is the degradation rate constant of HQ (% degraded/day), A is the collision factor, T is the 
absolute temperature in Kelvin, R is the gas constant (1.985 cal/mol/K), and Ea is the activation energy 
in cal/mol. 
2.5. In Vitro Permeation Studies Using Strat-M® Membranes 
Strat-M® membranes (Millipore, Billerica, MA, USA) were mounted between the donor and 
receptor chamber of Franz diffusion cells (Soham Scientific, Soham, UK) with an effective diffusion 
area of 1.76 cm2 and a cell volume of 12 ml filled with freshly phosphate-buffered solution (PBS, pH 
7.4). The diffusion cells were maintained at 37 ± 0.5 °C, and the fluid in the receptor chambers was 
stirred continuously at 600 rpm. Accurately weighed (200 mg) and prepared HQ formulations were 
loaded in the donor chambers and spread over a thin layer on the Strat-M® membrane. Samples (1 
mL) from the receptor chambers, at several time intervals (5 min, 10 min, 15 min, 30 min, 60 min, 120 
min, 180 min, 240 min, 360 min, and 480 min) were withdrawn for HPLC determination without 
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further dilution, and the volume was replaced immediately with fresh phosphate buffer solution to 
keep sink conditions. The cumulative amounts of HQ that permeated through the Strat-M® 
membrane were plotted as a function of time [3]. Each formulation was tested in triplicate. Regression 
analysis was used to calculate the slopes and intercepts of the linear portion of each graph. The 
following equation (Equation (3)) was applied to each formulation to calculate the steady-state flux:  
    =  
  
  
×                                   Equation (3)  
where Jss is the steady-state flux (µg/cm2/h), dC/dX is the amount of HQ permeating the membrane 
over time (µg/h), and A is the surface area of contact of the formulation [18]. The permeability 
coefficient (P) was calculated by using Equation (4): 
P = Jss/cd                                                      Equation (4) 
where cd is amount of drug applied in the donor compartment (200 mg of formulation equivalent 
to 10 mg of HQ). The diffusion coefficient was calculated by using the following equation:  
    =
 × 
 
                                                   Equation (5) 
where h is the thickness of the membrane. The enhancement ratio (ER) was calculated as the ratio of 
steady-state transdermal flux from each formulation compared to Formulation (1) [19]. 
2.6. In Vitro Permeation Studies using Healthy Mouse Skin 
Mouse skin was removed from a male-bred NMRI (8 weeks, 25 g) that had been previously 
euthanised according to the Ethical Committee Regulations of the University, Community of Madrid 
PROEX 041/18 (27/4/2018). The skin was placed flat in foil and frozen within a sealed plastic bag in 
the freezer (–20 °C), and was used within a month. The skin was shaved and suspended in 60 °C 
deionised water for 30 seconds, after which the underlying muscle tissue and hypodermis were 
manually removed. Skin was thawed in PBS pH 7.4 for 20 min prior to being mounted between the 
donor and receptor chamber of a Franz diffusion cell. Experiments were performed in quadruplicate, 
and a similar methodology was utilised when artificial skin membranes (Strat M® membrane, 
Millipore, Billerica, MA, USA) were used. 
2.7. Quantification of Drug Amount Trapped in Mouse Skin after In Vitro Permeability Assay 
Following each permeability study (6 h), the skin samples were wiped with an ethanol-
impregnated cotton bud to remove the excess of formulation. Samples were cut in half. One half was 
fixed using 4% paraformaldehyde (pH 7) and placed in the fridge for histological studies. The other 
half was weighed and homogenised with 2 mL of PBS pH 7.4 buffer. A 1:2 dilution with methanol 
was performed. The mixture was vortexed (2 min) and then centrifuged (10 min, 10,000 rpm). The 
supernatant was transferred into an HPLC vial and analysed for drug content using the HPLC 
method described below. 
2.8. HPLC Quantification for HQ and pBQ 
HQ and pBQ were isocratically eluted using a Hichrom (Reading, UK) Partisil 10 ODS C18 
reverse-phase column (200 × 4.6 mm, 5 µm) and a mobile phase that consisted of a monobasic 
phosphate buffer pH 3: methanol (95:5 v/v) with a flow rate of 1.5 mL/min. Absorbance was 
monitored at 289 nm for HQ and 252 nm for pBQ. The injection volume was set at 20 µL and 100 µL 
for stability and permeation studies, respectively. The retention time of HQ was 3.1 min, and it was 
5.2 min for pBQ. A linear regression calibration curve between 0.1–50 µg/mL was obtained to 
extrapolate the concentration values. 
2.9. Mechanistic Release Models 
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The permeability data of HQ from each formulation was fitted using different mathematical 
models in order to investigate the mechanism involved in the HQ release from the different 
formulations [20]: zero order (Equation (6)), first order (Equation (7)), Hixson–Crowell (Equation (8)), 
Higuchi (Equation (9)), and Korsmeyer–Peppas (Equation (10)): 
   =    +                                                              Equation (6) 
ln    = ln    +                                                          Equation (7) 
  
 / 
−    
 / 
=                                                          Equation (8) 
     =    √                                                           Equation (9) 
  
  
=    
                                                            Equation (10) 
where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the solution 
(most times, Q0 = 0), Q∞ is the initial amount of drug in the formulation; Qt/Q∞ is the fraction of drug 
release at time t; K0 is the zero-order release constant, K1 is the first-order release constant, Ks is a 
constant incorporating the surface–volume relation; KH is the Higuchi order release constant, KKP is a 
constant that describes the structural and geometric characteristics of the drug dosage form, and n is 
the release exponent that describes the drug release mechanism. The n can have a value of 0.5, 0.45, 
or 0.43 when the particle shape is a thin film, a cylinder, or a sphere, respectively, which corresponds 
to Fickian release controlled by diffusion. Anomalous non-Fickian transport is described when n is 
between those values and 1 (0.5 < n < 1 for thin films, 0.45 < n< 1 for cylinders, and 0.43 < n < 1 for 
spheres). n = 1 corresponds with zero-order release [21]. To test the applicability of the drug release 
model, the regression coefficient (R2) was calculated [22]. 
2.10. Skin Histological Analysis after Exposure to HQ Formulations 
Fixed mouse skin samples with 4% paraformaldehyde exposed to HQ formulations and healthy 
untreated NMRI skin samples were placed in Leica biopsy cassettes, and then dehydrated using a 
tissue processor (Shandon, Citadel 2000 Tissue Processor, Thermo Scientific, Basingstoke, UK). The 
dehydration process involved tissues automatically placed first in deionised water for 2 min followed 
by ascending concentrations of ethanol (2 h at 50%, 2 h at 75%, 2 h at 90%, and 2 h × 3 in 100% ethanol) 
and finally into Histoclear medium for 4 h (histological cleaning agent, Agar scientific, Stansted, UK) 
prior to paraffin wax embedding (3 h).   
Once the samples had been dehydrated following preparation, they were placed in metal 
moulds (Tissue Tek Stainless Steel Base Moulds for Uni-Cassettes and Process/Embedding Systems) 
and filled with preheated, melted paraffin wax (Histosec paraffin wax pastilles, Merck Millipore, 
Billerica, MA, USA) using a wax embedder (Leica EG1150 H Heated Paraffin Embedding Module, 
Wetzlar, Germany). Then, the filled moulds were placed on a cold plate (Leica EG1150 C Cold Plate 
Module) and once the paraffin had set, they were removed from the metal moulds and kept on the 
cold plate ready for use.  
The paraffin-embedded mouse skin samples were sectioned using a microtome (Leica RM-2235 
Microtome) attached to a 10-µm microtome blade (Leica Disposable Blade, high profile (818) (80 mm 
long, 14 mm high). Finely cut sections of samples were floated on a 40 °C water bath (Leica HI1210 
Water bath) to flatten the sections out. Then, the cut sections were placed on microscope slides 
(Shandon Colorfrost Plus Microscope slides, Thermo Scientific, Basingstoke, UK), dried on a hot plate 
(Leica HI1220 Flattening table, Leica Biosistems, Newcastle upon Tyne, UK) at 37 °C, and finally 
stained with haematoxylin and eosin (H&E).  
Slides were placed on a hot plate (Leica HI1220 Flattening table, Leica Biosistems, Newcastle 
upon Tyne, UK) at 60 °C for 15 min to allow the paraffin wax to melt using the IHC World for H&E 
staining method (IHC World, 2018) [23]. Then, heated slides were immersed in xylene (two sets, 10 
min in each) to completely remove residual paraffin wax, followed by treatment in two sets of ethanol 
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(both 100%) for 5 min each to dehydrate the samples. Slides were placed in a staining rack and coated 
with haematoxylin (0.1%) for 10 min, and then rinsed under tap water for 5 min. Excess haematoxylin 
was removed by applying acid alcohol (1% HCl 0.02 M in 70% Ethanol) for 5 seconds; then, slides 
were rinsed under tap water. Slides were immersed in Eosin (1% solution) for 5 min; then, slides were 
rinsed under tap water for 1 to 5 min. Stained specimen samples were placed in deionised water for 
3 min, followed by ascending grades of ethanol (50%, 70%, 95%) for 3 min each up to 100% ethanol 
for 6 min each for dehydration. Samples were placed into xylene for 6 min and then mounted in DPX 
mountant media and covered with glass microscope slide cover slips (22 × 22 mm, Menzel-Gläser, 
Braunschweig, Germany). The stained mouse skin sample slides were observed under a light 
microscope with an attached camera (GMX-L1500BHTG Biological, Trinocular Microscope with 
GXCAM-1.3, GT Vision Ltd, Stansfield, UK). Images were captured, saved, and analysed by using 
GXCapture7 software. 
2.11. Statistical Analysis 
Statistical analyses were performed via one-way ANOVA test using Minitab 16 (Minitab Ltd., 
Coventry, U.K.) followed by Tukey’s test. Statistical signiﬁcance was set at p < 0.05. A multivariate 
data analysis was performed using The Unscrambler® X software (CAMO Software, Norway). Eight 
variables (mean size in volume, span, viscosity, water content, stability at 25 °C and 40 °C at day 30 
expressed as percentage of remaining HQ, steady-state flux across mouse skin and Strat-M®) were 
analysed by principal component analysis (PCA). PCA was employed to study the systematic 
variability and the relationships between variables and scores (the four HQ formulations). The 
correlation loadings of the PCs were represented to understand the variance for each variable for a 
given PC, giving information about the source of the variability inside the dataset [24].  
3. Results and Discussion 
3.1. Characterisation of HQ Formulations 
The droplet size, mean viscosity, and water content of the four HQ formulations freshly 
prepared are illustrated in Table 2. The trend in droplet size expressed in volume, number, or area 
was the same in all the cases, in which F1 was the formulation with the highest droplet size (61.8 ± 
3.4 µm) followed by F2 (44.9 ± 4.5 µm), F4 (26.0 ± 1.9 µm), and F3 (8.3 ± 0.8 µm). In contrast, the 
polydispersity index showed that F3 and F4, even though they exhibited the smallest droplet size, 
had a twofold higher span compared to F1 and F2. Similar results were obtained for the viscosity: F3 
and F4 exhibited higher viscosity values than F1 and F2 at 15 rpm. Interestingly, the apparent water 
content of F1, F2, and F4 formulations was close to the real water content (50–70%) after preparation, 
while for F3, there was an important discrepancy, bearing in mind that the true water content was 
50.8% while only 16.8% was detected. This discrepancy can be related to F3 being capable of retaining 
water molecules in its physicochemical structure even at 105 °C, which probably can lead to a greater 
emollient activity than the other three formulations. 
Table 2. Mean droplet size expressed in volume (MV), area (MA), and number (MN), span, viscosity, 
and apparent water content of the different HQ formulations. 
Parameters F1 F2 F3 F4 
MV (µm) 61.8 44.9 8.3 26.0 
MN (µm) 12.1 15.2 1.0 0.9 
MA (µm) 38.4 32.9 3.0 7.3 
Span 1.9 1.4 3.2 3.5 
Viscosity (Pa·s) 88.8 99.0 113.2 156.6 
Apparent water content (%) 60.4 54.8 16.8 69.8  
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Figure 1 shows the rheological behaviour of the four HQ formulations after stress from 0 to 15 
rpm. Even though all of the emulsions exhibited a pseudoplastic behaviour and thixotropy, it is 
important to understand how differences in droplet size and polydispersity affect the different 
rheological properties amongst the formulations, as this impacts on the required force for the 
application of the formulation on the skin. A pseudoplastic behaviour is quite common in creams and 
emulsions, because the orientation of the particles changes to align with the direction of flow. The 
original orientation is restored over a period of time, after which the external force is removed. Unlike 
Newtonian fluids, the viscosity of pseudoplastic materials increases with decreasing droplet size, as 
shown for F3 and F4 versus F1 and F2. The flow behaviour in highly concentrated emulsions is 
governed by the total interfacial area. A change in droplet size at a constant volume fraction causes a 
horizontal shift in the viscosity versus the shear rate [25]. The thixotropy was more evident in F4, 
which probably is related to the high polydispersity of the formulation in terms of particle size, and 
hence, the longer time required for the particles to rearrange to its initial conformation. F4 also 
showed to some extent a Bingham pseudoplastic behaviour requiring a higher shear stress at low 
shear rates for the flow to start. This may be related to the ability of the different droplet sizes to 
exhibit a closer packing compared to uniform and larger droplet sizes, as in the case of F1 or F2. 
 
Figure 1. Rheograms of the four HQ formulations (n = 3). 
3.2. Physical and Chemical Stability 
Physical stability was studied as the evolution of the mean volume size and span values of 
samples stored at different temperatures over a three-month period (Figure 2). The most physically 
stable formulation was F3, whereas F1, F2, and F4 showed a significant increase in the particle size 
over time, and a greater span probably due to a coalescence process. The increase in particle size was 
more prominent at higher temperatures. The chemical stability of HQ formulations was studied 
based on the following three parameters: chromatic aberrations, HQ content (%), and p-BQ content 
(%). Figure 3 shows the differences among formulations in terms of chromatic aberrations. It is clearly 
observed that F3 was the most affected formulation by the chromatic aberrations, which was 
probably due to its higher oil content, whereas F4 was the less susceptible formulation even after 30 
days of storage at 40 °C. The antioxidant capacity of the Nourivan® base is clearly demonstrated in 
Figure 3. 
Figure 4 show the effect of temperature on the HQ degradation and pBQ formation of the 
different formulations. All of the formulations were stable (>95% HQ) after 30 days at 6 °C. However, 
temperature greatly affected the chemical stability of HQ. The degradation rates of HQ calculated by 
fitting the experimental data to a first-order reaction (R2 >0.9) showed that F3 was the most stable 
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formulation followed by F4 > F1 > F2 (Table 3). The degradation of HQ at 40 °C occurred at a threefold 
and 10-fold higher rate than at 25 °C and 6 °C, respectively. The activation energy calculated from 
the Arrhenius equation was 12.5 ± 2.3 Kcal/mol, which is actually associated with poor chemically 
stable drugs [26]. Regarding the pBQ (with recommended exposure limits of 0.1 ppm time weighted 
average, NIOSH 2018) [27], the levels found in the four HQ formulations were below 0.02% in all the 
conditions, in which F1 was the formulation with the lowest formation of pBQ. The levels of pBQ 
were reduced over time, which can be related to a secondary degradation of pBQ, and can explain 
why the values rose up to 30–60 days, but lowered after three months. 
 
 
Figure 2. Evolution of MV size (left) and polydispersity of size expressed as span (right) of samples 
stored at different temperatures in semilogarithmic scale. 
 
Figure 3. Chromatic aberrations on formulations stores during 30 days at different temperatures. 
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Figure 4. Chemical stability of HQ formulations upon storage at different temperatures expressed as 
a) HQ degradation and b) p-benzoquinone (pBQ) formation. 
Table 3. Degradation constants (percentage of degraded HQ/day) at different storage conditions.  
T(°C) F1 F2 F3 F4 
40 0.0107 0.0115 0.0048 0.0072 
25 0.0033 0.0046 0.0006 0.005 
6 0.001 0.0011 0.0002 0.001 
3.3. In Vitro Permeation Studies and Histological Analysis  
In vitro permeation studies were performed using a synthetic membrane (Strat-M®) and mouse 
skin (Table 4 and Figure 5). F3 exhibited the highest steady-state transdermal flux across both types 
of membranes. The enhancement ratio was significantly larger (2.26 and 5.67-fold across Strat-M® 
and mouse skin, respectively) than F1 (p < 0.05). Much greater flux was obtained across mouse skin 
than across Strat-M®, which is probably due to the low molecular weight of the HQ (110 g/mol) and 
its hydrophilicity (log P = 0.59), taking into account that the Strat-M® membrane has been validated 
for drugs that have larger molecular weights than HQ and are more hydrophobic in nature [28,29]. 
In addition, the shortest lag time was observed with F3, indicating that it had the fastest onset of 
action (p < 0.05). F4 also showed a superior permeation than F1, with an enhancement ratio of 1.58 
and 2.27 across Strat-M® and mouse skin, respectively. The better performance of F3 and F4 is 
associated with their chemical composition as well as their smaller droplet size. F2 exhibited a similar 
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permeability profile than F1, which could be because both of them have a larger droplet size and 
contain Beeler’s base as their major component. This correlation between particle size and permeation 
is clearly observed in Figure 6. The PCA correlation loading plot showed that the mean droplet size 
in volume was inversely correlated with the steady-state flux and the viscosity. 
Another factor that can potentially explain the differences in permeability amongst the four 
formulations is the drug release kinetic (Table 5). The release profiles can be best explained by the 
Higuchi and Korsmeyer–Peppas models, as the plots show high linearity (R2 > 0.99). The permeation 
of the four formulations across Strat-M® followed a Korsmeyer–Peppas release with n values ~ 1, 
whereas F3 and F4 formulations showed a release profile across mouse skin that is better explained 
by the Higuchi model compared to F1 and F2 (modelled by the Korsmeyer–Peppas release with an n 
value of 0.94). The Korsmeyer–Peppas model suggests a two-step release mechanism of the drug 
embedded in the matrix: polymer relaxation (matrix swelling) followed by diffusion [30]. In those 
systems with higher lag time, the model that best describes the release is the Korsmeyer–Peppas. In 
these cases, the lag time is related to the matrix swelling followed by a linear drug release, which 
corresponds to the secondary diffusion step according to the Korsmeyer–Peppas model. The n value 
is similar to one, which indicated that the release is also close to a zero-release kinetic. In the case of 
the permeation of F3 and F4 across the mouse skin, the lag time is negligible, indicating that the 
diffusion of the drug across the skin starts almost immediately. This ability is probably conferred by 
the effect of oleic acid in the olive oil base in F3, and the components of Nourivan® in F4. DMI can 
disrupt the stratum corneum lipid organisation, making it more permeable to HQ. However, DMI by 
itself does not increase the permeation across the skin (F2 has similar or lower permeability than F1). 
The combination of DMI with oleic acid and Nourivan® have an enhanced effect on the HQ diffusion 
coefficient [31,32]. 
Table 4. Comparison of skin permeation of HQ formulations (F) across synthetic (S.M. for Strat-M®) 
or natural (M.S. for Mouse skin) membranes. Key: Jss, steady-state transdermal flux calculated from 
the slope of the Cartesian plot of the cumulative amount of the drug present in the receptor 
compartment versus time; ER, enhancement ratio, calculated as the ratio of steady-state transdermal 
flux from each formulation compared to formulation 1; P, permeability coefficient calculated by using 
formula Jss/cd (cd is the amount of drug applied in the donor compartment, so 200 mg of formulation 
is equivalent to 10 mg of HQ); D, diffusion coefficient (cm2/h) calculated by using formula Jss = d.k/h×cd 
(where h is the thickness of the Strat-M® or mouse skin); NA, not applicable. 
F Membrane 
Jss 
(µg/cm2/h) 
Lag time (h) 
P 
(cm/h) x 102 
D  
(cm2/h) x 103 
ER 
Amount of HQ in 
the skin (mg/g) 
F1 S.M. 49.3 ± 2.4 0.95 ± 0.06 0.49 ± 0.02 0.54 ± 0.03 - NA 
F2 S.M. 39.3 ± 3.9 1.18 ± 0.09 0.39 ± 0.03 0.43 ± 0.04 0.8 ± 0.1 NA 
F3 S.M. 106.3 ± 6.5 0.47 ± 0.08 1.06 ± 0.08 1.17 ± 0.09 2.2 ± 0.2 NA 
F4 S.M. 78.1 ± 3.3 0.79 ± 0.07 0.78 ± 0.03 0.85 ± 0.03 1.6 ± 0.1 NA 
F1 M.S. 309.9 ± 66.3 0.35 ± 0.08 3.09 ± 0.66 4.31 ± 0.92 - 3.58 ± 1.21 
F2 M.S. 221.5 ± 43.1 0.42 ± 0.08 2.21 ± 0.42 3.10 ± 0.06 0.7 ± 0.1 2.50 ± 1.43 
F3 M.S. 1754.1 ± 184.9 0.12 ± 0.06 17.5 ± 1.82 24.5 ± 2.58 5.7 ± 0.6 1.36 ± 0.84 
F4 M.S. 700.5 ± 213.0 0.12 ± 0.03 7.00 ± 0.21 9.81 ± 0.25 2.3 ± 0.7 1.57 ± 0.78 
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Figure 5. In vitro permeability of HQ formulations across different membranes. a) Strat-M® 
membrane; b) Mouse skin. Key: -■- Formulation 1; -●- Formulation 2, -▲- Formulation 3; -▼- 
Formulation 4. # p-value < 0.05 compared to Formulation 1 and * p-value < 0.05 compared to 
Formulation 4. 
Another difference that can be pointed out amongst the four formulations is the amount of HQ 
that accumulated in the mouse skin after 6 h. The highest amount of drug was found after the 
exposure to F1 followed by F2, F4, and F3, which has an inverse relation to the steady-state flux. One 
of the explanations to justify these results is that F1 and F2 contain mostly Beeler’s base, which is 
anionic and has a higher potential to interact with the positively charge proteins of the skin (such as 
filaggrin, a histidine-rich matrix protein of keratinised epidermis [33], and hence, it is retained in the 
stratum corneum and epidermis in higher concentration instead of passing across [34,35]. 
Figure 7 shows photomicrographs of untreated and exposed to HQ mouse skin. Fig 7 shows 
some signs of toxicity such as a non-well-defined stratum corneum layer, which could explain the 
highest permeability across skin compared to Strat-M®, as well as the infiltration of some 
inflammatory cells and epithelial necrosis. It is worthy to note that within the skin exposed to the F1 
formulation at greater magnification (40×), some crystalline deposits were observed, which can be 
attributable to the HQ accumulated in the stratum corneum and epidermis. This can justify the larger 
amounts of HQ found in the mouse skin after exposure to the F1 formulation. Hence, the cause of 
low-skin bioavailability for F1 appears to be the reservoir that the drug can form on and in the stratum 
corneum as well as deposition on the skin. The crystallisation of drugs in skin following topical 
application has been previously described as being the vehicle employed in the formulation key for 
this to happen [36].  
Table 5. Mechanistic release kinetics of HQ from topical formulations (F). Regression coefficient (R2) 
values from the permeability data (expressed in %/cm2) through synthetic (S.M.) or natural 
membranes (M.S.) using the following kinetic equations: zero order, first order, Higuchi, Hixson–
Crowell and Korsmeyer–Peppas. 
F Membrane Zero order First order Higuchi Hixson–Crowell Korsmeyer–Peppas 
F1 S.M. 0.9851 0.9846 0.9299 0.9848 0.9919 
F2 S.M. 0.9735 0.9728 0.9047 0.9731 0.9923 
F3 S.M. 0.9919 0.9901 0.9448 0.9908 0.9951  
F4 S.M. 0.9923 0.9918 0.9474 0.9919 0.9950 
F1 M.S. 0.9797 0.9833 0.9767 0.9822 0.9835 
F2 M.S. 0.9801 0.9822 0.9723 0.9815 0.9821 
F3 M.S. 0.9517 0.9852 0.9917 0.9774 0.9837 
F4 M.S. 0.9653 0.9760 0.9920 0.9728 0.9863 
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Previous studies on humans have shown that the dermal absorption of HQ can reach a 
bioavailability of 45% after 24-h application [37]. The prolonged use of HQ topical products is 
associated with exogenous ochronosis, and major concerns have been raised due to the carcinogenic 
potential of HQ reported by animal studies [38,39]. In 2014, the United States Cosmetic Ingredient 
Review [40] stated that the use of HQ in cosmetic formulations is safe at concentrations below 1% for 
discontinuous and brief periods. However, in some countries such as Japan, cosmetics can contain 
up to a 10-fold higher concentration of HQ [41]. In Europe, HQ creams and ointments can be 
prescribed by dermatologists at different dose strengths up to 10%, and hence, the risk of toxicity and 
adverse effects raises exponentially. For this reason, it is crucial to understand how the HQ should 
be formulated, bearing in mind that the use of different permeation enhancers can tune the 
transdermal delivery of HQ significantly.  
 
Figure 6. Multivariate analysis of the physicochemical properties of the four HQ formulations and 
their permeability across mouse skin and Strat-M®. a) Three-dimensional (3D) scatter plot comparing 
MV and Jss across mouse skin and Strat-M®; b) Correlation loading plot obtained after principal 
component analysis (PCA). The average value of the following parameters was included for the MVA 
analysis: mean size in volume (MV), viscosity, span, water content, stability at 25 °C and 40 °C at 30 
days expressed as the percentage remaining of HQ, Jss across mouse skin and Strat-M®. 
One current European cosmetics regulation (Cosmetics Regulation 1223/2009) restricts and 
precludes the use of HQ in cosmetics. However, dermatologists still need HQ for the treatment of 
patients with serious hyperpigmentation problems, and typically, high HQ doses are prescribed and 
used under specialist supervision. Toxicity is related to high permeation that is not limited to the 
skin. Utilising olive oil or Nourivan® as vehicles in the formulation can enable high local permeation 
and thus the delivery of lower and most likely safer doses. Until HQ topical medicines are not 
commercialised by pharmaceutical companies endorsed with well-designed clinical studies, it is 
important that clinicians should prescribe not only the active ingredient and the dose strength, but 
also the excipients and the modus operandi for the extemporaneous compounding of HQ 
formulations in order to limit the risk of variability both in efficacy and toxicity. In our study, we 
have shown that the substitution of the most common anionic base (Beeler’s Base) employed by 
Spanish pharmacists during the formulation of HQ topical creams by other alternative excipients 
such as olive oil or Nourivan® can lead to significantly higher permeation across the skin and hence, 
lower doses would be required to elicit the same dermatological effect. Otherwise, the risk of toxicity 
may be exacerbated. Olive oil or Nourivan® have also shown a superior performance in terms of 
physical and chemical stability compared to those formulations containing Beeler’s base, which can 
lead to higher patient compliance. 
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Figure 7. Photomicrographs of untreated and exposed to HQ formulations mouse skin. A) Untreated 
skin (20× magnification); B) Skin exposed to HQ1 formulation (20× magnification); C) Skin exposed 
to HQ1 formulation (40× magnification); D) Skin exposed to HQ2 formulation (20× magnification); E) 
Skin exposed to HQ3 formulation (20× magnification); F) Skin exposed to HQ4 formulation (20× 
magnification). Key: 1- Stratum corneum, 2- Hair follicle, 3- Sebaceous gland, 4- Possible 
inflammatory cell, 5- Possible epithelial necrosis, 6- Possible drug depot accumulation. 
4. Conclusions 
The physicochemical stability, permeation, and cytotoxicity of four different semisolid O/W 
formulations with 5% HQ has been evaluated: F1 containing Beeler´s base plus antioxidants, F2 with 
Beeler´s base and DMI as a solubiliser, F3 formulated with olive oil and DMI, and F4 utilising 
Nourivan®, a skin-moisturising and antioxidant base, along with DMI. The emulsion with the 
smallest droplet size after dilution was F3 followed by F4 < F2 < F1. Regarding their physicochemical 
stability, F3 showed the lowest degradation rate of HQ and the smallest variation in droplet size over 
time; however, F3 exhibited a greater chromatic aberration than the other three formulations. In 
contrast, F1 had the lowest formation of pBQ, which may be related to the absence of DMI in the 
formulation.  
An inverse correlation was established between the mean droplet size in volume and the steady-
state flux, which explains why F3 exhibited the shortest lag time and the highest permeation across 
both types of membranes with enhancement ratios of 2.26 and 5.67-fold across Strat-M® and mouse 
skin, respectively, compared to F1. In contrast, the largest amount of HQ found in the skin after 6 h 
of exposure was F1 followed by F2, which can be justified by the interaction between the cationic 
proteins in the skin and the anionic nature of the Beeler´s base (sodium lauryl sulphate). Some signs 
of toxicity were found on the skin after 6 h of exposure with all of the formulations. In conclusion, it 
is crucial that clinicians prescribe topical HQ formulation indicating not only the dose strength but 
also the excipients and the modus operandi for the extemporaneous compounding to limit the risk 
of variability both in efficacy and toxicity.  
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: 
Virgin olive oil characteristics. All of the physicochemical tests were conformed with Pharmacopeia 
requirements. Table S2: Nourivan® characteristics. Composition: Purified water, cetearyl alcohol, 
polysorbate 60, C13-C16 isoparaffin, C12-C14 isoparaffin, C13-C15 alkane, glyceryl stearate, 
polyacrylate 13, polyisobutene, polysorbate 20, polyurethane-39, stearyl behenate, cetyl alcohol, 
ascorbic acid, benzoic acid, sodium bisulfite, sorbic acid, tocopheryl acetate. 
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